Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer

19 Oct 2020

Abstract excerpt

PURPOSE Accurate monitoring of therapeutic response remains an important unmet need for patients with metastatic breast cancer (MBC). Analysis of tumor genomics obtained via circulating tumor DNA (ctDNA) can provide a comprehensive overview of tumor evolution. Here, we evaluated ctDNA change as an early prognostic biomarker of subsequent radiologic progression and survival in MBC. PATIENTS AND METHODS Paired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35050782
DOI: 10.1200/po.20.00117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerPMID 35050782Read ↗

Analysis of circulating tumor DNA to monitor metastatic breast cancer.Semantic proximity Read ↗

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.Semantic proximity Read ↗

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.Semantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read ↗

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast CancerSemantic proximity Read ↗

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.Semantic proximity Read ↗

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.Semantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.